It is not dangerous game hunting, or high stakes poker. This is the most dangerous game. It makes you feel good about your future, that house with land you desire, the new truck you wish to buy and it all seems so near. All looks so good, why not invest all and get those big returns?
Sept 15, 2015 4:46 p.m. ET
Novavax Inc. NVAX, +0.36% shares advanced in the extended session Tuesday after the vaccine developer announced a promising animal study for one of its vaccine candidates. Novavax shares rose 4.5% to $10.63. The company said pregnant guinea pigs given the vaccine candidate transferred protection to their offspring from respiratory syncytial virus, a lead cause of infant infection.
Aug 15, 2016 at 3:59PM
Turning to Novavax, this biotech is scheduled to report top-line phase 3 results for its F-protein nanoparticle RSV vaccine candidate in elderly adults this quarter. If this experimental vaccine hits pay dirt its ongoing phase 3 study and goes on to become one of the first treatments ever approved for RSV -- a virus that infects the lungs -- it would undoubtedly be a huge win for shareholders.
After all, Novavax's experimental RSV vaccine candidate is forecast to generate somewhere between $1 billion and $6 billion in sales as a preventative RSV treatment in adults aged 60 or older, depending on its pricing scheme.
The company's goal, assuming a positive readout, is to file for the vaccine's regulatory approval in the U.S. in 2017 and with European authorities by 2018. This proposed regulatory time frame means that the vaccine could reach the U.S. market by 2018 and become commercially available in Europe by 2019.
Sept 15, 2016 6:15 p.m. ET
Novavax Inc. NVAX, +0.36% shares plummeted in the extended session Thursday after the vaccine company said one of its lung infection vaccines did not meet endpoints in a late-stage clinical trial. Novavax shares plunged 84% to $1.30 on volume of more than 16 million shares. The company said its study in older adults for a vaccine against respiratory syncytial virus, which can cause bronchitis and pneumonia, did not meet primary or secondary clinical trial goals.
Sept 15, 2015 4:46 p.m. ET
Novavax Inc. NVAX, +0.36% shares advanced in the extended session Tuesday after the vaccine developer announced a promising animal study for one of its vaccine candidates. Novavax shares rose 4.5% to $10.63. The company said pregnant guinea pigs given the vaccine candidate transferred protection to their offspring from respiratory syncytial virus, a lead cause of infant infection.
Aug 15, 2016 at 3:59PM
Turning to Novavax, this biotech is scheduled to report top-line phase 3 results for its F-protein nanoparticle RSV vaccine candidate in elderly adults this quarter. If this experimental vaccine hits pay dirt its ongoing phase 3 study and goes on to become one of the first treatments ever approved for RSV -- a virus that infects the lungs -- it would undoubtedly be a huge win for shareholders.
After all, Novavax's experimental RSV vaccine candidate is forecast to generate somewhere between $1 billion and $6 billion in sales as a preventative RSV treatment in adults aged 60 or older, depending on its pricing scheme.
The company's goal, assuming a positive readout, is to file for the vaccine's regulatory approval in the U.S. in 2017 and with European authorities by 2018. This proposed regulatory time frame means that the vaccine could reach the U.S. market by 2018 and become commercially available in Europe by 2019.
Sept 15, 2016 6:15 p.m. ET
Novavax Inc. NVAX, +0.36% shares plummeted in the extended session Thursday after the vaccine company said one of its lung infection vaccines did not meet endpoints in a late-stage clinical trial. Novavax shares plunged 84% to $1.30 on volume of more than 16 million shares. The company said its study in older adults for a vaccine against respiratory syncytial virus, which can cause bronchitis and pneumonia, did not meet primary or secondary clinical trial goals.
